Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2026)

Amneal Pharmaceuticals' Revenue history runs 10 years deep, the most recent figure standing at $722.5 million for Q1 2026.

• On a quarterly basis, Revenue rose 3.9% year-over-year to $722.5 million in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 7.62% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 8.05% from the prior year.
• Revenue declined to $722.5 million in Q1 2026 per AMRX's latest filing, from $814.3 million in the prior quarter.
• Across five years, Revenue topped out at $814.3 million in Q4 2025 and bottomed at -$1.6 billion in Q4 2022.
• The 5-year median for Revenue is $659.2 million (2024), against an average of $526.4 million.
• Across the five-year window, Revenue sank 394.8% in 2022 and jumped 138.98% in 2023, its largest moves.
• Year by year, Revenue stood at -$1.6 billion in 2022, then surged by 138.98% to $617.0 million in 2023, then advanced by 18.4% to $730.5 million in 2024, then rose by 11.47% to $814.3 million in 2025, then decreased by 11.27% to $722.5 million in 2026.
• Per Business Quant, the three latest AMRX Revenue figures stand at $722.5 million (Q1 2026), $814.3 million (Q4 2025), and $784.5 million (Q3 2025).